Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
Jaeseong Oh, Lei Tang, In‐Jin Jang, Yingxin Li et al.
Citations
2 citations
Journal
Expert Opinion on Investigational Drugs
Topics
Complement system in diseases
Field-Weighted Citation Impact (FWCI)
0.48
article
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
Jaeseong Oh, Lei Tang, In‐Jin Jang, Yingxin Li, Joo Young Na, Yunting Zhu, Amy Zhao
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Expert Opinion on Investigational DrugsVol. 33(10)
Institutions
Seoul National University (KR), Seoul National University Hospital (KR), Sanofi (China) (CN), The Ohio State University (US)